Onco - Approach to Patient with Cancer Flashcards

1
Q

Most significant risk factor for cancer overall

A

Age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

2/3 of all CA cases were those in what age?

A

> 75 y.o.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Most common cause of cancer deaths

A

Lung CA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

second most common cause of cancer deaths in females?

A

Breast cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

second most common cause of cancer deaths in males?

A

colorectal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Arrange the following from most to least common cause of cancer deaths in males:

Colorectal, Prostate, Lung

A

Lung> colorectal> prostate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Arrange the following from most to least common cause of cancer deaths in females:

Colorectal, breast, Lung

A

Lung> breast> colorectal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Overall lifetime risk of developing cancer (men)

A

44%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Overall lifetime risk of developing cancer (women)

A

38%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Continents ranking on cancer cases:

Africa, Central/South America, Europe, North America, Australia/NewZealand, Asia

A

Asia > Europe > North America > Central/South America > Africa > Australia/New Zealand

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Second most common cancer

A

Breast CA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Cancers more common in developed countries

A

Lung
Breast
Prostate
Colorectal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Cancers more common in developing countries

A

liver
cervical
esophageal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Most common cancers in Africa

A

Cervical
Breast
Liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

9 Modifiable risk factors responsible for 1/3 of cancers worldwide

A

SOAP FUCCS

Smoking
Obesity
Air Pollution
Physical inactivity
low Fruit and vegetable consumption
Unsafe Sex
Contaminated injection
Consumption of Alcohol
Smoke (indoor) from household fuels
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Importance of Review of Systems in History taking for possible cancer patients

A

to catch symptoms of metastatic disease or a paraneoplastic syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Cornerstone of cancer diagnosis. Diagnosis should never be made without this

A

Invasive tissue biopsy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

T/F fine needle aspiration is acceptable diagnostic procedure for thyroid nodules

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Molecular marker for Burkitt’s lymphoma

A

t(8;14) translocation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Best approach to management of cancer patient

A

Multidisciplinary Collaboration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

First priority in patient management after diagnosis of cancer is established and shared with the patient

A

determine extent of disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Relationship of curability of tumor with tumor burden

A

inversely proportional

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

T/F Ideally, tumor will be diagnosed before symptoms develop or as a consequence of screening efforts. A very high proprotion of such patients can be cured.

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

True of Cancer diagnosis EXCEPT

a. A patient with a metastatic disease process that is defined as cancer on biopsy may have no apparent primary site of disease
b. Particular attention should be focused on ruling out the most lethal cause
c. Both
d. Neither

A

B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Major determinants of treatment outcome in cancer patients

A

Performance status

Staging

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Give four importance of cancer staging

A
  1. determines optimal treatment plan
  2. Helps to evaluate prognosis
  3. helps to determine effectivity of treatment plan
  4. Provides a standardized description of disease extent
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Karnofsky Performance index

Normal activity with effort, some signs or symptoms of the disease

A

80

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Karnofsky Performance index

Requires considerable assistance and frequent medical care

A

50

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Dead

A

0

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Performance status scales (ECOG)

Normal activity

A

0

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Performance status scales (ECOG)

Symptomatic but ambulatory

A

1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Performance status scales (ECOG)

Dead

A

5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Performance status scales (ECOG)

In bed >50% of the time

A

3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Performance status scales (ECOG)

Bed ridden

A

4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Performance status scales (ECOG)

in bed <50% of the time

A

2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Staging based on PE, Radiographs, isotopic scans, CT scans, other imaging

A

Clinical Staging

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Staging based on information obtained via intraoperative palpation, resection of regional lymph nnodes and / or tissue adjacent to the tumor, and inspection and biopsy of organs commonly involved in disease spread.

A

Pathologic Staging

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

International federation of gynecologists and obstetricians classification: gynecologic CA :: __________: colorectal CA

A

Dukes classifcation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Dukes classification: colorectal CA :: _________ : Hodgkin’s disease

A

Ann Arbor classification

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Meaning of ECOG

A

Eastern cooperative oncology group

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Karnofsky performance status with poor prognosis

A

<70

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

ECOG performance status with poor prognosis

A

> =3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

T/F

Morphology is capable of discerning certain distinct subsets of patients whose tumors have different set of abnormalities

A

F; not capable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

T/F

tumors that look quite different from one another histologically can share genetic lesions that preduct responses to treatments

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

most common side effects of cancer treatment (3-4)

A

nausea and vomiting, febrile neutropenia, myelosuppresion

46
Q

T/F treatment induced toxicity is quite acceptable if the goal of therapy is palliation

A

F; less acceptable

47
Q

T/F new symtpoms developing the the course or cancer treatment should not be assumed to be reversible

A

F; it should always be assumed reversible until proven otherwise

48
Q

three symptoms of reversible intercurrent cholecyistits

A

anorexia
weight loss
jaundice

49
Q

What should be done if a patient on cancer treatment develops CNS symptoms that look like metastatic disease or may mimic paraneoplastic syndromes

A

pursue a definitive diagnosis; may require repeat biopsy

50
Q

Cancer treatment response

> 50% reduction in the sum of the products of the perpendicular diameters of all measurable lesions

A

Partial Response

51
Q

Definition of complete response to cancer treatment

A

disappearance of all evidence of the disease

52
Q

Cancer treatment response

appearance of any new lesion or an increase in >25% in the sum of the products of the perpendicular diameters of all measurable lesions.

A

Progressive disease

53
Q

Tumor shrinkage or growth that does not meet any criteria for other 3 responses

A

Stable disease

54
Q

Cancer treatment response

RECIST definition of progressive disease

A

increase of 20% in the sums of the longest diameters by RECIST

55
Q

Site of involvement that are considered unmeasurable

A

bone

56
Q

Pattern of involvement conisdered unmeasurable

A

lymphangitic lung

diffuse pulmonary infiltrates

57
Q

No respoonse is complete without ____ documentation

A

biopsy

58
Q

T/F biopsy is not needed to evaluate partial responses especially if there is clear objective progression

A

T

59
Q

Definition of minimal residual disease negativity

A

If flow cytometric assay/ genetic assay do not determine the presence of residual tumor cells (thechniques can reliably detect as few as 1 tumor cell among 10,000 cells)

60
Q

Incidence of depression in cancer patients

A

25%

61
Q

Two major symptoms of depression

A

dysphoria (depressed mood)

anhedonia (loss of interest in pleasure)

62
Q

Minor symptoms of depression

A
appetite change
sleep problems
psychomotor retardation or agitation
fatigue
feelings of guilt or worthlessness
inability to concentrate
suicidal ideation
63
Q

2 main drug classes for medical therapy of depression

A
  1. Serotonin reuptake inhibitor

2. TCA

64
Q

Examples of SRI for depression in cancer

A

paroxetine
sertraline
fluoxetine

65
Q

Examples of TCA for depression in cancer

A

amitriptyline

desipramine

66
Q

Response should be expected in antidepressant therapy within

A

4-6 weeks

67
Q

Minimum duration of antidepressant medication

A

6 months after resolution of symptoms

68
Q

Frequency of follow up during the first year of completion of treatment, and being disease free

A

monthly

69
Q

Frequency of follow up during the third year of completion of treatment, and being disease free

A

every other month

70
Q

Frequency of follow up during the 5th year of completion of treatment, and being disease free

A

every 6 months

71
Q

Major investigation performed during follow up after cancer patients become disease free

A

history and physical exam

72
Q

% of patients in pain with progressive disease

A

75%

73
Q

Major concerns of supportive care (7)

A

PPENNED

Pain
Psychosocial support
Effusions
Nutrition
Nausea
End of Life Decisions
Death and Dying
74
Q

% of pain in cancer patients that is caused by the tumor itself

A

70%

75
Q

% of patients that will have pain relief from pharmacologic intervention

A

85%

76
Q

Three forms of emesis

A

Acute emesis
Delayed emesis
Anticipatory emesis

77
Q

most common variety of emesis

A

acute emesis

78
Q

When does acute emesis occur?

A

within 24 hrs of tx

79
Q

when does delayed emesis occur?

A

1-7 days after treatment

80
Q

When does anticipatory emesis occur?

A

Before administration of chemotherapy drug

81
Q

Where is the vomiting center located

A

medulla

82
Q

Emesis related to bowel inflammation from chemotherapy

A

Delayed emesis

83
Q

T/F

Anti emetic agents should be given just as chemotherapy is given

A

False, before

84
Q

Antiemetic and dosage given for mild to moderate emitogenic agents, to prevent acute emesis

A

prochloperazine 5-10 mg PO or

25 mg PR

85
Q

Drug given to enhance efficacy of prochlorperazine

A

Dexamethasone 10-20mg IV

86
Q

Give 4 highly emitogenic chemotherapy drugs

A
  1. Cisplatin
  2. Mechlorethamine
  3. Dacarbazine
  4. Streptozocin
87
Q

Drug for highly emitogenic chemotherapeutic drugs

A

Ondansetron 8mg PO every 6h

88
Q

Timing of Ondansentron 8mg PO every 6h for acute emesis

A

6-24 h before treatment

89
Q

T/F Emesis is easier to prevent than to alleviate

A

T

90
Q

Best strategy for preventing anticipatory emesis

A

control emesis in the early cycles of therapy

91
Q

True about effusions EXCEPT

a. fluid may accumulate in the pleural cavity, pericardium, or peritoneum
b. Asymptomatic malignant effusions require tx
c. Symptomatic effusions occuring in tumors responsive to systemic therapy usually do not require local treatment
d. symptomatic effusions occuring in tumors unresponsive to systemic therapy may require local tx in all patients
e. B and D
f. C and D

A

E

92
Q

most common cancers causing pleural effusion

A

Lung Cancer
Breast Cancer
Lymphoma

93
Q

Effusion/serum protein ratio for pleural effusion

A

> =0.50

94
Q

Effusion/serum LDH ration

A

=>0.60

95
Q

Initial management for symptomatic pleural effusion in cancer

A

Thoracentesis

96
Q

When will chest tube drainage be done in pleural effusion in cancer?

A

if symptoms recur within 2 weeks after thoracentesis

97
Q

In chest tube drainage, fluid is aspirated until the flow rate is

A

<100mL in 24h

98
Q

When will chest tube be pulled out?

A

if <100mL drains over the next 24h

99
Q

What is done after chest tube is removed?

A

radiograph is taken 24 h later

100
Q

Tumor derived factors causing altered metabolism in cancer patients

A

bombesin

adrenocorticotropic hormone

101
Q

Host derived factors causing altered metabolism in cancer patients

A

TNF
IL1
IL6
GH

102
Q

Threshold for nutritional intervention

% unexplained body weight loss

A

<10%

103
Q

Threshold for nutritional intervention

serum transferrin level

A

<1500 mg/L (150 mg/dL)

104
Q

Threshold for nutritional intervention

serum albumin

A

<34 g/L (3.4g/dL)

105
Q

Progestational agent advocated as pharmacologic intervention to improve nutritional status

A

Megestrol acetate

106
Q

Most pervasive and threatening concern for cancer patients

A

fear of relapse

107
Q

what is Damocles sydrome

A

fear of relapse

108
Q

Most common causes of death in patients with cancer (4)

A

infection
respiratory failure
hepatic failure
renal failure

109
Q

% of patients with dyspnea preterminally

A

70%

110
Q

Three phases of unsuccessful cancer treatment

A
  1. optimism
  2. tumor recurs: hope to live with disease
  3. imminent death: adjustment
111
Q

fatiuge, disengagement from patients and colleagues and a loss of self fulfillment in attending physician of cancer patient

A

burnout syndrome